Cookies help us to provide you a better service. In using our services, you agree with our use of cookies. Read More

February 27, 2018   |   News

BIAL and WhanIn signed an Exclusive Licensing Agreement for Eslicarbazepine Acetate in South Korea

February 27th, 2018 - BIAL and WhanIn Pharm. Co., Ltd, announced today an exclusive license agreement for the commercialization of Zebinix® (eslicarbazepine acetate) in South Korea.

Eslicarbazepine acetate is BIAL’s proprietary once daily anti-epileptic for the treatment of partial-onset seizures, with or without secondary generalization. It is marketed in several European markets and in the US and Canada.

“BIAL is committed to addressing the needs of patients and healthcare professionals worldwide and the control of seizures is a continual challenge. We are delighted to partner with WhanIn and thus be able to offer this treatment option for patients with focal epilepsy across South Korea,” comments António Portela, Chief Executive Officer of BIAL, Porto, Portugal.

Further information is available in the Press Release below.

Share